Product image of Mavenclad (Cladribine) supplied by GNH India

Mavenclad

Active Ingredient:
Cladribine
Origin:
EU

Mavenclad (Cladribine)

Cladribine, the active ingredient in Mavenclad, is a purine nucleoside analog presented as 10 mg and 20 mg tablets for oral administration. It is indicated for the treatment of relapsing‑remitting multiple sclerosis and active secondary progressive multiple sclerosis in adult patients by selectively depleting circulating lymphocytes and modulating immune activity.

GNH India supplies Mavenclad as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with a focus on quality assurance and regulatory compliance across EU and global markets.

Manufacturer / TM Owner

Merck Europe B.V.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Mavenclad (cladribine) is used in disease‑modifying therapy for multiple sclerosis, targeting immune‑mediated disease activity.

  • Relapsing‑remitting multiple sclerosis: reduces annual relapse rate and slows disability progression.
  • Active secondary progressive multiple sclerosis: decreases disease activity and may delay worsening of disability.
  • Adults with multiple sclerosis: provides an intermittent oral dosing option for long‑term disease management.

How It Works

  • Cladribine is a purine nucleoside analog that is preferentially taken up by lymphocytes and phosphorylated intracellularly. Incorporation into DNA triggers strand breaks and apoptosis, leading to selective depletion of B and T lymphocytes. This effect is sustained for months after each treatment cycle, allowing intermittent dosing while maintaining disease control.

Side Effects

Cladribine may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

  • Headache: mild to moderate headache reported.
  • Nausea: transient nausea, often mild.
  • Fatigue: general tiredness during treatment.
  • Lymphopenia: reduced lymphocyte counts, usually reversible.

Serious or Rare Side Effects

  • Severe infections: opportunistic infections such as herpes zoster.
  • Malignancy: rare reports of cancer development.
  • Autoimmune hepatitis: uncommon liver inflammation.

Precautions & Warnings

Before prescribing Mavenclad, clinicians should consider several safety measures.

  • Monitor lymphocyte counts: perform regular blood tests to detect lymphopenia.
  • Screen for infections: assess for active infections before initiating therapy.
  • Avoid live vaccines: live attenuated vaccines may be ineffective or unsafe during treatment.
  • Pregnancy considerations: use only if benefits outweigh risks; discuss with healthcare provider.
  • Renal function: adjust use in patients with severe renal impairment.
  • Store at ambient temperature: keep tablets below 25 °C in original packaging, protect from moisture.

Avoid Interactions

Cladribine can interact with other medicines, requiring careful management.

Major Interactions (Avoid)

  • Live vaccines: concurrent administration can cause severe infection.
  • Immunosuppressive agents: combined use may excessively suppress immunity.

Moderate Interactions (Monitor Closely)

  • Non‑live vaccines: efficacy may be reduced; schedule appropriately.
  • CYP3A4 modulators: strong inducers or inhibitors may alter cladribine metabolism.
  • Anticonvulsants: some may affect blood counts; monitor hematology.

Frequently Asked Questions

Mavenclad contains cladribine and is used as a disease‑modifying therapy for adults with relapsing‑remitting multiple sclerosis or active secondary progressive multiple sclerosis. It works by reducing immune‑mediated disease activity and slowing disability progression.

Cladribine is a purine nucleoside analog that enters lymphocytes, is phosphorylated, and becomes incorporated into DNA. This causes DNA strand breaks and triggers apoptosis, leading to selective depletion of B and T cells that drive the autoimmune response in multiple sclerosis.

The prescribed dose of Mavenclad is determined by the treating physician based on the patient’s weight, disease status, and laboratory results. Dosing regimens are individualized and should follow the approved prescribing information.

The safety of Mavenclad in pregnancy and lactation has not been established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and decisions should be made in consultation with a healthcare professional.

To order Mavenclad, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mavenclad offers an oral, intermittent dosing schedule, unlike many injectable or continuous‑infusion disease‑modifying therapies. Its mechanism of selective lymphocyte depletion differs from agents that target specific cytokines or cell surface receptors, providing an alternative option for patients who prefer oral administration.

Mavenclad tablets should be stored at ambient temperature, preferably below 25 °C, in the original blister pack. They must be kept away from moisture and direct sunlight to maintain stability and potency.

Mavenclad is taken orally as tablets. The treatment course consists of two annual dosing periods, each consisting of several tablets taken on specific days, as directed by the prescribing physician.

The most serious risks include severe infections due to lymphocyte depletion, potential development of malignancies, and rare cases of autoimmune hepatitis. Patients should be monitored regularly for signs of infection and abnormal laboratory values.

Mavenclad is contraindicated in patients with active infections, those who have received live vaccines within four weeks, and individuals with severe renal impairment unless dose adjustments are made. It should also be avoided in patients with known hypersensitivity to cladribine.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Cladribine

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT